Literature DB >> 2787294

Interleukin-1 beta induces tumor necrosis and early morphologic and metabolic changes in transplantable mouse tumors. Similarities with the anti-tumor effects of tumor necrosis factor alpha or beta.

F Belardelli1, E Proietti, V Ciolli, P Sestili, G Carpinelli, M Di Vito, A Ferretti, D Woodrow, D Boraschi, F Podo.   

Abstract

Peri-tumoral injection of recombinant human interleukin-1 beta in mice transplanted s.c. with Friend erythroleukemia cells (FLC) resulted in marked inhibition of tumor growth and increased survival. However, in vitro treatment of FLC (745 or 3Cl-8) with IL-1 beta barely inhibited cell multiplication. IL-1 beta, injected into established solid tumors, induced marked morphologic changes. Vascular congestion and focal extravasation of erythrocytes were observed as early as 6 hr after injection with IL-1 beta of FLC and L1210 tumors and HeJ16 fibrosarcomas. Focal areas of disaggregation of tumor cells and tumor necrosis were observed 6 and 24 hr after IL-1 injection. These morphologic changes were similar to those observed in FLC tumors or HeJ16 fibrosarcomas treated with TNF-alpha or beta. These cytokines determined morphological changes in tumor blood vessels of FLC tumors within 1 hr of injection. Freshly dissected FLC tumors and their tissue extracts were studied by Nuclear Magnetic Resonance (NMR) spectroscopy, shortly after peri-tumoral injection of IL-1 beta or TNF-beta. After 6 hr, both cytokines induced a 3-fold reduction in the levels of two catabolites, glycerophosphorylcholine and glycerophosphorylethanolamine, an accumulation of sn-glycerol 3-phosphate and a more than 10-fold increase in the choline/phosphorylcholine ratio. These results are similar to those reported for TNF-alpha, and can be interpreted on the basis of an activation of glycerophosphorylcholine phosphodiesterase (EC 3.1.4.2) and partial inhibition of choline kinase (EC 2.7.1.32). IL-1 beta and TNF-beta (like TNF-alpha) also induced alkaline shifts (0.10-0.25 units) in the average intratumoral pH value. We suggest that alterations of tumor blood vessels may be the primary events in solid tumors treated with IL-1 beta or TNF. Such alterations lead to early changes in tumor metabolism and subsequent tumor cell degeneration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2787294     DOI: 10.1002/ijc.2910440121

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.

Authors:  E Proietti; G Greco; B Garrone; S Baccarini; C Mauri; M Venditti; D Carlei; F Belardelli
Journal:  J Clin Invest       Date:  1998-01-15       Impact factor: 14.808

2.  Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.

Authors:  G R Peplinski; K Tsung; E D Whitman; J B Meko; J A Norton
Journal:  Ann Surg Oncol       Date:  1995-03       Impact factor: 5.344

3.  Production of interleukin-1 beta and tumour necrosis factor-alpha in patients with benign or malignant ovarian tumours.

Authors:  J Punnonen; P K Heinonen; T Kuoppala; C T Jansen; R Punnonen
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic Friend leukemia cells: host antitumor mechanisms and marked effects on established metastases.

Authors:  V Ciolli; L Gabriele; P Sestili; F Varano; E Proietti; I Gresser; U Testa; E Montesoro; D Bulgarini; G Mariani
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

5.  A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.

Authors:  Y Nihei; Y Suga; Y Morinaga; K Ohishi; A Okano; K Ohsumi; T Hatanaka; R Nakagawa; T Tsuji; Y Akiyama; S Saito; K Hori; Y Sato; T Tsuruo
Journal:  Jpn J Cancer Res       Date:  1999-09

6.  Antitumor activity of recombinant human interleukin-1 against heterotransplanted human non-Hodgkin lymphomas in nude mice.

Authors:  T Miyamoto; S G Wu
Journal:  Jpn J Cancer Res       Date:  1990-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.